Wall Street Zen Upgrades Corvus Pharmaceuticals (NASDAQ:CRVS) to "Hold"
Wall Street Zen upgraded Corvus Pharmaceuticals (NASDAQ:CRVS) from a "sell" to a "hold" rating in a recent report. Other analysts have mixed views, with Weiss Ratings maintaining a "sell" rating, while Barclays set an "overweight" rating with a $16.00 price target. Corvus has a market cap of $567.57 million and reported an EPS of ($0.12), beating estimates. Institutional investors hold 46.64% of the stock, which has a current price of $7.60, with a one-year range of $2.54 to $10.00.
Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday.
Get Corvus Pharmaceuticals alerts:
Several other research analysts also recently issued reports on CRVS. Weiss Ratings reiterated a "sell (d-)" rating on shares of Corvus Pharmaceuticals in a research report on Wednesday, October 8th. Mizuho set a $13.00 target price on shares of Corvus Pharmaceuticals in a research note on Wednesday, October 29th. Finally, Barclays assumed coverage on shares of Corvus Pharmaceuticals in a research note on Monday, October 13th. They set an "overweight" rating and a $16.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Corvus Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $14.25.
View Our Latest Report on CRVS
Corvus Pharmaceuticals Price Performance
Shares of CRVS opened at $7.60 on Friday. The company has a market capitalization of $567.57 million, a P/E ratio of -14.34 and a beta of 0.56. Corvus Pharmaceuticals has a one year low of $2.54 and a one year high of $10.00. The business's 50 day simple moving average is $6.84 and its 200-day simple moving average is $5.10.
Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. On average, sell-side analysts anticipate that Corvus Pharmaceuticals will post -0.63 EPS for the current fiscal year.
Institutional Trading of Corvus Pharmaceuticals
Institutional investors and hedge funds have recently made changes to their positions in the business. Towerview LLC grew its stake in shares of Corvus Pharmaceuticals by 64.5% during the first quarter. Towerview LLC now owns 127,500 shares of the company's stock worth $405,000 after purchasing an additional 50,000 shares during the period. American Century Companies Inc. boosted its holdings in Corvus Pharmaceuticals by 103.9% during the first quarter. American Century Companies Inc. now owns 89,265 shares of the company's stock worth $284,000 after buying an additional 45,491 shares during the last quarter. Wellington Management Group LLP acquired a new position in shares of Corvus Pharmaceuticals during the 1st quarter worth about $333,000. Jump Financial LLC bought a new stake in shares of Corvus Pharmaceuticals in the 1st quarter valued at about $143,000. Finally, OMERS ADMINISTRATION Corp increased its stake in shares of Corvus Pharmaceuticals by 9.0% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 82,300 shares of the company's stock valued at $262,000 after acquiring an additional 6,800 shares during the last quarter. Institutional investors own 46.64% of the company's stock.
Corvus Pharmaceuticals Company Profile
(Get Free Report)Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
Read More
- Five stocks we like better than Corvus Pharmaceuticals
- How to Calculate Return on Investment (ROI)
- OpenAI's Restructuring Sets up What Could Be the Biggest IPO Ever
- Consumer Discretionary Stocks Explained
- 2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail
- What is a Dividend King?
- CrowdStrike Partners With CoreWeave But Investors Sell the News
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?
Before you consider Corvus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.
While Corvus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
